New cancer drug BI 3810944 enters first human tests

NCT ID NCT07224425

Recruiting now Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three weeks for up to two years, with regular health checks and imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 3810944
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumours or melanoma who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 69 participants. The main goal is safety and dosing, not yet proof of effectiveness. Many early-stage cancer drugs do not advance to later testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA SOLID TUMOURS

Contacts and locations

Locations

Cliniques Universitaires Saint-Luc
NOT_YET_RECRUITING

Brussels, 1200, Belgium
Radboud Universitair Medisch Centrum
NOT_YET_RECRUITING

Nijmegen, 6525 GA, Netherlands
Tennessee Oncology, PLLC - Elliston Place Plaza DDU
RECRUITING

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
UZ Leuven
NOT_YET_RECRUITING

Leuven, 3000, Belgium
University of Louisville
RECRUITING

Louisville, Kentucky, 40202, United States
University of Virginia Health System
NOT_YET_RECRUITING

Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.